TICKERNERD
Menu
VYGRVYGRHealthcare · Biotechnology

VYGR Stock Forecast: Voyager Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 29 Oct 2026
$1.76
−4.35% on the day

The 11 Wall Street analysts covering Voyager Therapeutics, Inc. hold a median 12-month price target of $12 — +581.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 61 of 100 as at 28 Oct 2026 — in the upper half.

Market cap
$106.6M
Ticker Nerd rank
61/ 100
Median analyst target
$12
Analysts covering
11
Revenue$3.2M−39.1% y/y
Operating income−$26.4M
Net income−$24.5M
Free cash flow−$25.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.4%
1M
−33.3%
YTD
−55.2%
1Y
−61.8%
From 52W high
−64.8%
From 52W low
+1.7%
$1.73
$5.00
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

VYGR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Voyager Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 28 Oct 2026
61/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
85
Size
73
Issuance
66
Volatility
65
Accruals
56
Revisions
51
Quality
50
Value
47
Momentum
20

Growth (85): Sales and profits are climbing, and climbing faster than before.

Momentum (20): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

VYGR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VYGR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00$25.00Jan 26Apr 26Jul 26Oct 26VYGRHigh $25Median $12Low $8

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says11 analysts
11 Buy0 Hold0 Sell
Low $8Median $12High $25

The green dot is the last close — the median target sits +581.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
10 Aug 2026HC Wainwright & Co.ReiteratesBuy$25
10 Aug 2026HC Wainwright & Co.ReiteratesBuy—
17 Mar 2026HC Wainwright & Co.ReiteratesBuy$25
17 Mar 2026HC Wainwright & Co.ReiteratesBuy—
12 Nov 2025HC Wainwright & Co.MaintainsBuy—
15 Sept 2025HC Wainwright & Co.ReiteratesBuy—
7 Aug 2025WedbushMaintainsOutperform—
8 Apr 2025HC Wainwright & Co.ReiteratesBuy—
13 Mar 2025Canaccord GenuityMaintainsBuy—
13 Mar 2025HC Wainwright & Co.ReiteratesBuy—
12 Mar 2025Cantor FitzgeraldReiteratesOverweight—
12 Mar 2025WedbushReiteratesOutperform—
12 Mar 2025Wells FargoMaintainsOverweight—
3 Mar 2025HC Wainwright & Co.ReiteratesBuy—
27 Jan 2025HC Wainwright & Co.ReiteratesBuy—
10 Jan 2025Cantor FitzgeraldInitiatesOverweight—
2 Dec 2024CitigroupInitiatesBuy—
14 Nov 2024Canaccord GenuityMaintainsBuy—
14 Nov 2024HC Wainwright & Co.ReiteratesBuy—
24 Oct 2024HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

VYGR appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

VYGR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 29 Oct 2026, Voyager Therapeutics, Inc. returned −61.8% against +13.1% for the S&P 500, dividends included.

VYGR vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26VYGRS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

VYGR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
0
Fundamentals

Voyager Therapeutics, Inc. (VYGR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
6.1×

Cheaper than 64% of US stocks

Price / sales
3.1×

Cheaper than 39% of US stocks

Price / book
0.7×

Cheaper than 79% of US stocks

EV / EBITDA
−0.2×

Cheaper than 64% of US stocks

Growth & margins
Revenue growth (YoY)
−39.1%

Higher than 7% of US stocks

Earnings growth (YoY)
−39.1%

Higher than 13% of US stocks

Gross margin
—
Operating margin
−833.9%

Higher than 6% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−54.1%

Higher than 21% of US stocks

Return on assets
−27.3%

Higher than 15% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Voyager Therapeutics, Inc. (VYGR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Voyager Therapeutics, Inc. has a market value of $106.6M and an enterprise value of $22.8M.

  • Revenue in the twelve months to 30 June 2026: $34.5M. The latest quarter shrank 39.1% year on year.

  • Net income over the same four quarters: −$107.7M, a −312.6% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.81.

  • Free cash flow in the twelve months to 30 June 2026: −$121.4M.

  • Shares outstanding: 61.3M.

  • Trailing P/E: 6.1×; forward P/E: −1.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Voyager Therapeutics, Inc. employs 141 people — $244K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 28 Oct 2026

Data provided by Twelve Data

Peers

VYGR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
VYGRVoyager Therapeutics, Inc.$106.6M61
IMUXImmunic, Inc.$108.7M26
SEERSeer, Inc. (California)$111.9M81
CBUSCibus, Inc.$107.4M38
NRXPNRX Pharmaceuticals, Inc.$112.8M17
ANIXAnixa Biosciences, Inc.$113.0M68
OKUROnKure Therapeutics, Inc.$106.2M54

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Voyager Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VYGR news & analysis

Voyager's Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer's Disease to Be Featured in Poster Presentations at CTAD 2026

GlobeNewsWire · 27 Oct 2026neutral

Voyager Therapeutics announced that posters on its investigational tau-lowering gene therapy VY1706 and clinical-stage anti-tau antibody VY7523 will be presented at the CTAD 2026 conference in Boston, November 16–19.

Why it matters — The presentations will feature two of Voyager’s tau-targeting Alzheimer’s disease programs.

Voyager: Maintaining A Strong Buy For Q4 PET Imaging Data AD And More

Seeking Alpha · 23 Oct 2026positive

The Seeking Alpha article maintains a Strong Buy view of Voyager, citing its anti-tau programs for Alzheimer’s disease and expected VY7523 PET imaging data and VY1706 first-in-human dosing in Q4 2026. It also points to partnerships and funding that the article says support the company’s cash runway into 2028.

Why it matters — The cited clinical milestones, partnerships, and funding are factors VYGR watchers may track as the Alzheimer’s programs advance.

Voyager Announces CEO Succession Plan, Appoints Robin Swartz President

GlobeNewsWire · 21 Oct 2026neutral

Voyager Therapeutics appointed Chief Business and Operating Officer Robin Swartz as President, effective immediately. Swartz is expected to succeed Alfred W. Sandrock, Jr., M.D.

Why it matters — The announcement outlines a leadership transition at Voyager, a development relevant to investors following the company.

Voyager Therapeutics, Inc. (VYGR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Seeking Alpha · 10 Sept 2026neutral

Voyager Therapeutics presented at the Wells Fargo 21st Annual Healthcare Conference, with a transcript of the presentation published on Seeking Alpha. The presentation covered the company's discussion with conference attendees regarding its business.

Why it matters — A conference presentation provides investors with direct insight into Voyager's strategy and updates from company leadership.

Voyager to Present at Upcoming Investor Conferences

GlobeNewsWire · 1 Sept 2026neutral

Voyager Therapeutics announced that it will participate in upcoming investor conferences, including a fireside chat at the Wells Fargo 21st Annual Healthcare Conference. The company said it would present at these events to discuss its work in leveraging genetics to treat neurological diseases.

Why it matters — The announcement indicates Voyager will have opportunities to communicate its business to the investment community at scheduled industry conferences.

FAQ

Frequently asked questions about VYGR stock

What is the VYGR stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Voyager Therapeutics, Inc. have a median 12-month price target of $12, with estimates ranging from $8 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VYGR stock a buy right now?

Of the 11 analysts covering Voyager Therapeutics, Inc., 11 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Voyager Therapeutics, Inc. 61 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VYGR?

As at 28 Oct 2026, Voyager Therapeutics, Inc. ranks 61 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (85 of 100).

Will VYGR stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +581.8% from the last close, and Ticker Nerd's factor model ranks Voyager Therapeutics, Inc. 61 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VYGR stock forecast for 2030?

No analyst covering Voyager Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VYGR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $25 over the next 12 months.

How has VYGR stock performed over the past year?

Voyager Therapeutics, Inc. returned -61.8% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Voyager Therapeutics, Inc. do?

Voyager Therapeutics, Inc. is a biotechnology company focused on developing gene therapies and other genetic medicines for severe neurological diseases.

What is the latest news on VYGR?

The most recent item we track (GlobeNewsWire, 27 Oct 2026): "Voyager's Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer's Disease to Be Featured in Poster Presentations at CTAD 2026". Voyager Therapeutics announced that posters on its investigational tau-lowering gene therapy VY1706 and clinical-stage anti-tau antibody VY7523 will be presented at the CTAD 2026 conference in Boston, November 16–19.

Company

About Voyager Therapeutics, Inc.

Voyager Therapeutics, Inc. is a biotechnology company focused on developing gene therapies and other genetic medicines for severe neurological diseases. The company’s current programs center on disorders such as Alzheimer’s disease, amyotrophic lateral sclerosis, Huntington’s disease, Parkinson’s disease, and frontotemporal dementia. Its pipeline includes tau-focused and other neuroscience candidates, while its TRACER platform is designed to support adeno-associated virus-based delivery for targeted therapies. Voyager Therapeutics works at the intersection of genetics, neurology, and drug delivery, aiming to create treatments that address conditions with limited therapeutic options. Founded in 2013 and headquartered in Lexington, Massachusetts, the company plays a specialized role in the biotechnology market through its focus on neurogenetic research and clinical-stage development.

CEO Ms. Trista Morrison · 141 employees · United States · https://www.voyagertherapeutics.com